Zydus Lifesciences Limited (Formerly known ... Oxemia. It launched Ujvira, (Trastuzumab Emtansine biosimilar) in India, which is the first biosimilar of an Antibody Drug Conjugate (ADC) Kadcyla ...

Zydus Lifesciences Limited received final approval from the US Food and Drug Administration (USFDA) to manufacture Ketoconazole Shampoo, 2 per cent, according to the announcement issued by the ...

The stock of Zydus Lifesciences has been in a steady decline since August last year after facing resistance at ₹1,300. After witnessing some consolidation between ₹940 and ₹1,000 in December ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Zydus Lifesciences Ltd. is a Public Limited Listed company incorporated on 15/05/1995 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Nippon India Small Cap Fund - Direct (IDCW) 467.76 29,95,942 0.92 Nippon India Small Cap Fund - Direct (G) 467.76 29,95,942 0.92 Nippon India Small Cap Fund - Direct ...

Zydus Lifesciences launches ANVIMO, a breakthrough drug for preventing Cytomegalovirus infection in transplant patients, offering a safer and more affordable treatment option. Mar 05, 2025 15:16 Zydus ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

*Ministry of Corporate Affairs, 2019, Company/LLP Data, (Government of India administrative body to govern and regulate corporate affairs through the Companies Act ...

Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2025 ,inter alia, to consider and approve unaudited financial results of the ...